Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
Clinical trial NCT01883362 · COMPLETED
Trial details
- NCT number
- NCT01883362
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-06
- Primary completion
- 2018-04-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.